ERBB2 and head and neck squamous cell carcinoma: In a preclinical trial administering afatinib, a human HNSCC cell line with an overexpression of HER2 was used to generate cetuximab-resistant clones from a cetuximab-sensitive bladder cancer cell line in vivo.